Healthcare -
Biotechnology - NASDAQ - US
$ 54.8
-1.03 %
$ 6.97 B
Market Cap
18.15
P/E
HALO - COST OF REVENUE
Cost of Revenue HALO - Halozyme Therapeutics, Inc.
192 M
LAST VALUE
53.71%
2 YEAR CAGR
80.16%
5 YEAR CAGR
40.88%
10 YEAR CAGR